Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.-Reference-Cited by-同舟云学术

Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:102-102
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Long Georgina V.¹,Stroyakovskiy Daniil²,Gogas Helen³,Levchenko Evgeny⁴,De Braud Filippo G.⁵,Larkin James M. G.⁶,Garbe Claus⁷,Jouary Thomas⁸,Hauschild Axel⁹,Grob Jean Jacques¹⁰,Chiarion-Sileni Vanna¹¹,Lebbe Celeste¹²,Mandalà Mario¹³,Millward Michael¹⁴,DeMarini Douglas James¹⁵,Irani Jhangir G¹⁵,Jin Fan¹⁵,Swann R. Suzanne¹⁵,Mookerjee Bijoyesh¹⁵,Flaherty Keith¹⁶

Affiliation:

1. Melanoma Institute Australia and The University of Sydney, North Sydney, Australia

2. Moscow City Oncology Hospital #62, Chemotherapy Department, Moscow, Russia

3. 1st Department of Medicine, Medical School, University of Athens, Athens, Greece

4. Petrov Research Institute of Oncology, Saint Petersburg, Russia

5. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

6. The Royal Marsden NHS Foundation Trust, London, United Kingdom

7. University of Tübingen, Tübingen, Germany

8. Hôpital François Mitterrand, Pau, France

9. University of Kiel, Kiel, Germany

10. Aix-Marseille University, Hopital de la Timone, Marseille, France

11. Veneto Oncology Institute, Padova, Italy